BigHat Bio
Sangeetha Iyer currently serves as the Director of Alliance and Portfolio Management at BigHat Biosciences since February 2024 and has held the position of Scientific Advisor for the Association for Creatine Deficiencies since September 2019. Previously, Sangeetha worked as a Senior Manager in Program Management at Pfizer's Emerging Sciences and Innovation Unit from March 2021 to February 2024, overseeing project value delivery. Sangeetha also contributed as a Senior Scientist at Denali Therapeutics and as the Director of Preclinical Development at Perlara PBC, where Sangeetha was pivotal in advancing orphan drugs into clinical trials. With a foundation in neurodegenerative disorders and rare genetic diseases, Sangeetha's academic credentials include a PhD in Molecular Pharmacology from the University of Pittsburgh School of Medicine and a Bachelor of Science in Pharmaceutical Sciences from the Institute of Chemical Technology.
This person is not in any teams
This person is not in any offices
BigHat Bio
1 followers
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.